Esther Granell Hospital de la Santa Creu i Sant Pau Barcelona. Spain NEUROIMAGING IN FXTAS Can we predict conversion of premutation.

Slides:



Advertisements
Similar presentations
Discuss the relationship between phenotype and genotype in Fragile X syndrome. Louise Williams 06/03/2008.
Advertisements

Patients with early-onset Alzheimer’s disease: high field MRI findings. Fidel Núñez*1, Daniel Alcolea2, Esther Granell1, Manel De Juan1, Yolanda Vives3,
Interpretation of magnetic resonance imaging in the chronic phase of traumatic brain injury Jussi Laalo 1, Timo Kurki 2, Olli Tenovuo* 3 1 Department of.
Management of Early Dementia Dr Eleanor Mullan Consultant Psychiatrist Mental Health Services for Older People South Lee, Cork Feb 2011.
Frontotemporal Dementia
Young Onset Neurodegeneration study. Neurology at the Memory Clinic Dr Thomas Monaghan SpR in Neurology Memory, Cognitive Studies and Behavioral Neurology.
Presymptomatic HD Disease onset currently defined by clinical detection of motor abnormalities Questions: 1) Are more subtle but clinically important signs.
Significance of White Matter Hyperintensities in MCI Charles DeCarli University of California at Davis Alzheimer’s Disease Center Imaging of Dementia and.
Mild Cognitive Impairment as a Target for Drug Development Steven H. Ferris, Ph.D. Silberstein Aging and Dementia Research Center New York University School.
Dementia with Lewy Bodies
Causes, diagnosis, characteristics and interventions Karen Stewart EMR 6052 University of South Florida, St. Petersburg.
Fragile X Laboratory Testing: Background and Quality Improvement Opportunities (part 1 of 2) Elaine Lyon, Ph.D. University of Utah/ARUP Laboratories Association.
FreeSurfer Applications. What is it used for? Tools wielded: – Cortical thickness – Surface-based group analysis – Subcortical structure measurements.
Screening for Stroke and Cognitive Impairment Chapter 2: Background.
Dementia Research Group MRI, rates of atrophy and Alzheimer’s disease Nick Fox Dementia Research Group Institute of Neurology, UCL Queen Square, London.
A ACHOUR, S JERBI OMEZZINE, S YOUNES 1, S BOUABID, MH SFAR 1, HA HAMZA. Department of Medical Imaging, Tahar Sfar University Hospital Center, Mahdia, Tunisia.
Alzheimer’s Assessment Assessing the Cognitive-Linguistic effects of Alzheimer’s.
A 62-year-old man with progressive action tremor and a 74-year-old man with progressive ataxia Teaching NeuroImages Neurology Resident and Fellow Section.
Neuroimaging studies of normal aging The effects of normal aging on cognition Neuroimaging as a scientific tool The physiological basis of cognitive changes.
Cognitive Impairment Disorders. Assessing Brain Damage  Mental status examination  Information about current behavior and thought including orientation.
Defining Mild Cognitive Impairment Steven T.DeKosky, M.D. Director, Alzheimer’s Disease Research Center University of Pittsburgh Pittsburgh, PA.
NEURORADIOLOGY: NR33. RASMUSSEN'S ENCEPHALITIS IN ADULT: A REPORT CASE L. EL ASSASSE, S. BOUTACHALI, T. AMIL, A. HANINE, S. CHAOUIR, A. DARBI. Radiology.
COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.
Multiple Sclerosis A chronic, progressive central nervous system disease with a disseminating demyelination of the nerve fibers of the brain and spinal.
ASNR 2015 Poster# EP-19 Effect of Chemotherapy on Brain Structure and Cognition in Older Women with Breast Cancer: a Brain MRI Study 1 Bihong T. Chen MD.
American Association of Neuropathologists: 2011 Diagnostic Slide Session Jeremy Deisch, M.D. Dennis Burns, M.D. Charles White III, M.D.
MRI as a Potential Surrogate Marker in the ADCS MCI Trial
Brain Metabolites in Patients with Asymptomatic Versus Symptomatic HIV-associated neurocognitive disorder: A 7 Tesla MR Spectroscopy Study Mohamed MA,
Do Instrumental Activities of Daily Living Predict Dementia at 1- and 2- Year Follow-Up? Findings from the Development of Screening Guidelines and Diagnostic.
Brain Atrophy in Type 2 Diabetes Regional distribution and influence on cognition Featured Article: Chris Moran, M.B., B.C.H., Thanh G. Phan, P.H.D., Jian.
Understanding Mild Cognitive Impairment. Objectives Understand the concept of MCI Identify risk factors for progression to dementia Review clinical trial.
CHANGES IN BRAIN MORPHOLOGY ASSOCIATED WITH OBSTRUCTIVE SLEEP APNEA Mary J. Morrell et al Presented by Karen Hu PSYCH 260.
FRAGILE X SYNDROME (FXS)
Alabama Brief Cognitive Screener (ABCs)
The Alzheimer’s Disease Challenge: Take Your Knowledge Further ALZHEIMER’S DISEASE AND ITS MANAGEMENT: AN OVERVIEW.
Identifying and Tracking Changes in Cognition Related to NPH Sheldon Herring, Ph.D. Clinical Director Outpatient Brain Injury and Young Stroke Program.
White Matter Structural Integrity in Healthy Aging Adults and Patients With Alzheimer Disease: A Magnetic Resonance Imaging Study Bartzokis, et al. UCLA.
Neurobiology of Dementia Majid Barekatain, M.D., Associate Professor of Psychiatry Neuropsychiatrist Isfahan University of Medical Sciences Ordibehesht.
Apolipoprotein E and Gray Matter Loss in Mild Cognitive Impairment and Alzheimer’s Disease Spampinato MV, Goldsberry G, Mintzer J, Rumboldt Z Medical University.
Sven Haller Haller, Nguyen, Rodriguez, Emch, Gold, Bartsch, Lovblad, Giannakopoulos.
The Role of MRI in Perinatal Anoxic Ischaemic Brain Injury
Presented by: Vidyaningtyas BA, MD Yanuarita T, MD Widagdo S, MD.
MR SPECTROCOPY AND MRI TO MEASURE TREATMENT OF NEURODEGENERATION MICHAEL W. WEINER Professor of Radiology, Medicine, Psychiatry, and Neurology, U.C.S.F.
Advanced brain imaging and neurodegenerative disorders. Dott.ssa Ingrid Inches.
Adeline SL Ng, Amanda RJ Ng, Ivane Chew, Nagaendran Kandiah Department of Neurology, National Neuroscience Institute, Singapore APOE4 status modulates.
Sint Lucas-Andreas Hospital, Amsterdam
CASES SERIES BRAIN FDG PET SCAN IN DEMENTIA PATIENTS
Frontotemporal Lobar Degeneration:
Wolfram Syndrome: Classic Imaging Findings of an Uncommon Disease Eric Carolan, MD Jonathan M Morris, MD Control #1520 Poster EE-12.
CEREBROTENDINOUS XANTHOMATOSIS Sheri Harder* Paggie Kim * Miriam Peckham * Teresa LaBarte ŧ Departments of Radiology (Division of Neuroradiology)* and.
All Hands Meeting 2004 Ontologies for Data Mediation Christine Fennema-Notestine, Ph.D.
Rosa Maria Moresco University of Milan Bicocca
Center for Neurological Restoration, Cleveland Clinic Foundation
An Open Label Study of Allopregnanolone Treatment for
ULTRASONOGRAPHY AND MR IMAGING IN PROGRESSIVE SUPRANUCLEAR PALSY
Acknowledgements and Contact
Evidence of Morphologic Differences in Children with Down Syndrome who Develop Infantile Spasms. Nicholas Phillips1,3 , Asim Choudhri2, James Wheless1,
PPMI in the Medical Literature
The Ageing Brain Fergus Doubal October 2007.
Sébastien Jacquemont, Randi J
Reisa Sperling, Elizabeth Mormino, Keith Johnson  Neuron 
Fragile-X–Associated Tremor/Ataxia Syndrome (FXTAS) in Females with the FMR1 Premutation  R.J. Hagerman, B.R. Leavitt, F. Farzin, S. Jacquemont, C.M.
Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome  Randi Hagerman, MD, Dr Paul.
Adam P. Spira, Ph.D. Associate Professor, Department of Mental Health
Fluid-attenuated inversion recovery magnetic resonance imaging at the onset of the clinical investigation (A, B) and 2 months later (C, D). Fluid-attenuated.
Left middle frontal cortex, caudate nuclei
New assessment of hepatic encephalopathy
NEUROIMAGING FINDINGS OF RARE NEURODEGENERATIVE DISEASES RELATED TO DEMENTIA SYMPTOMS INTRODUCTION: Neurodegenerative diseases are diversified group of.
Hello, my name is Attakias and today I will be presenting a study on…
Defining diagnostic brain MRI markers in early MSA
Presentation transcript:

Esther Granell Hospital de la Santa Creu i Sant Pau Barcelona. Spain NEUROIMAGING IN FXTAS Can we predict conversion of premutation carriers?

BACKGROUND Fragile-X-associated Tremor/Ataxia Syndrome (FXTAS) is a late onset neurodegenerative disorder occurrying in carriers of a premutation expansion (55 to 200 repeats) of the Fragile X Mental Retardation (FMR1) gene

BACKGROUND NORMAL <54 CGG FULL MUTACION >200 CGG PREMUTATION CGG Fragile X Syndrome (FXS) FMR1 gene RNAm absent protein (methylation) (no transcription) FMR1 gene RNAm translation FMR1protein Fragile X Tremor Ataxia Syndrome (FXTAS) FMR1 gene excess RNAm normal or low protein Toxic gain-of-function: inclusion formation and neurological dysfunction

Diagnostic criteria  Major Radiological: WM, MCP and brainstem hyperintensities  Minor Radiological: brain, WM lesions moderate/severe brain atrophy  Major Clinical: intentional tremor, gait distubances  Minor Clinical: parkinsonism, loss of short memory executive disturbances Some FXTAS develop cognitive decline and eventually dementia, this having been mainly described in men. Up to date, it remains unknown which carriers will develop FXTAS and cognitive decline late in life “Definitive” disease: 1 major radiological + 1 major clinical “Probable”disease: 1 major radiological + 1 minor or 2 major clinical “Possible disease”: 1 minor + 1 major radiological

PURPOSE  To investigate if 3T MRI markers can differentiate FXTAS from non-FXTAS subjects, which may be potentially useful in predicting conversion of premutation carriers to FXTAS  To evaluate the relationship between MRI markers and cognitive-neuropsychological disturbances

METHODS Prospective, cross-sectional study of 44 subjects (30 premutation carriers and 14 controls),aged 33-80, matched for age and sex  3T (Philips Intera 2.1) MRI included 3D FLAIR and 3D-T1 MPRAGE. Conventional, previously described MRI findings were assessed by two experienced neuroradiologists  Neurological and neuropsychological evaluations :executive, memory, attention, global intelligence, and conductual  Cortical thickness (Freesurfer) and hippocampal volume (FS) and hippocampal shape (SPHARM) were analyzed on 3D MPRAGE images searching for potential MR markers  Statistical analysis included group-comparisons (Student´s t-test and one-way ANOVA) and a General Lineal Model

MRI findings in FXTAS patients included:  Middle cerebellar peduncle, brainstem, and cerebral white matter hyperintensities  Cerebellar, brainstem and brain atrophy RESULTS

brain atrophylocationMTL a.brainstem a.HIcerebellar a.MCP HIWM HI premutated ++F,P,T / cups,dots premutated +F / cups,dots premutated +F,P--+++dots < 20 premutated +F,P dots premutated +F,T,P-+-+++cups,dots > 20 premutated /3 dots premutated +F,P, ant. T /dots, cups premutated +F,P dots premutated ++F,T / cups,dots premutated +F,P dots premutated +---/+/- +F,P dots premutated +Global F,P,T+-++Slight1 dot premutated , 2 dots premutated ++F,P-+-+++dots premutated -` premutated +F----+3dots premutated +++F,T,P premutated ++F,P (few) premutated ++F,P,T premutated ++F,P

brain atrophylocationMTL a.brainstem a.HIcerebellar a.MCP HIWM HI premutated ++F,P,T / cups,dots premutated +F / cups,dots premutated +F,P--+++dots < 20 premutated +F,P dots premutated +F,T,P-+-+++cups,dots > 20 premutated /3 dots premutated +F,P, ant. T /dots, cups premutated +F,P dots premutated ++F,T / cups,dots premutated +F,P dots premutated +---/+/- +F,P dots premutated +Global F,P,T+-++Slight1 dot premutated , 2 dots premutated ++F,P-+-+++dots premutated -` premutated +F----+3dots premutated +++F,T,P premutated ++F,P (few) premutated ++F,P,T premutated ++F,P

RESULTS 11 patients fulfilled FXTAS-criteria (women and men), 2 women having dementia: 1a1b 1c 2a 2b2c These 2 women having FXTAS and dementia showed predominant frontal and temporal lobe atrophy, and white matter hyperintensities

RESULTS-Cortical thickness  There was selective decrease in cortical thickness in frontal and temporal regions, already present in the premutation state FXTAS-Elder PreElder Pre-Elder Control Young Pre-Young Control

Young pre-Young conElder Pre–Elder conFXTAS-Elder Pre LH Rostralmiddlefrontal Superiorfrontal × Precentral Lateraloccipital Parahippocampal Anteriorcingulate Posteriorcingulate RH Superiorfrontal Caudalmiddlefrontal Inferiorparietal Insula Anteriorcingulate Posteriorcingulate 9.7 × Parahippocampal RESULTS-Cortical thickness

RESULTS- Hippocampal volume and shape  Additionally, there were changes in hippocampal volume and its shape in the premutated and FXTAS state, more profound in those patients with dementia. Hippocampal volume in D FTXAS <non D FXTAS<Elder Pre (p=0.015 and 0.037) Young pre-Young controlFXTAS-Elder preD FXTAS-non D FXTAS

On neuropsychology, there was evidence of prefrontal and temporal impairment in premutated patients along the disease process  (FrBSe) Frontal System Behavior Scale: Apathy, dishinibition and executive disfunction in premutated patients: Premutated vs Control (Total scale p= 0.021) FXTAS vs Elder pre (Apathy p=0.087) D FXTAS vs. Non-D FXTAS ( Apathy P=0.04)  Left hippocampal cognitive disturbances: AVLT (Auditory Verbal Learning Test) Immediate AVLT: FXTAS vs Premutated (p=0.042) Delayed AVLT: D FXTAS vs non-D FXTAS (p=0.074) RESULTS-Neuropsychology

CONCLUSION  There are MRI changes already present in the premutated state in the frontal and temporal brain regions  These reflect impairment of related brain functions. 3T MRI may provide biomarkers, which could be clinically useful

REFERENCES I 1) Jacquemont, S, et al.Fragile X Premutation Tremor/Ataxia Syndrome: Molecular, Clinical, and Neuroimaging Correlates. Am. J. Hum. Genet. 72:869–878, ) Rodriguez-Revenga L, et al. Motor and mental dysfunction in mother-daughter transmitted FXTAS. Neurology 2010 (in press) 3)A. Inagakia, A. Iidab, M. Matsubarac and H. Inagakid. Positron emission tomography and magnetic resonance imaging in spinocerebellar ataxia type 2: a study of symptomatic and asymptomatic individuals. European Journal of Neurology 2005, 12: 725–728 4)M.R.R. Gonçalves, L. P. Capelli, R. Nitrini, E. R. Barbosa, C. S. Porto, L. T. Lucato and A. M. Vianna-Morgante. Atypical clinical course of fxtas: rapidly progressive dementia as the major symptom. Neurology 2007;68; )S. Jacquemont, R.J Hagerman, P.J Hagerman, M.A Leehey. Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1. Lancet Neurol 2007 Jan; 6 (1): 45-55

REFERENCES II 5)S. Jacquemont, R.J Hagerman, P.J Hagerman, M.A Leehey. Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1. Lancet Neurol 2007 Jan; 6 (1): ) M. A. Leehey, E. Berry-Kravis, S. Min, D. A. Hall, C. D. Rice, L. Zhang, J. Grigsby, C. M. Greco, A.Reynolds, R. Lara, B J. Cogswell, S. Jacquemont, D.R. Hessl, F. Tassone, R. Hagerman. Progression of Tremor and Ataxia in Male Carriers of the FMR1 Premutation. Movement Disorders 2007; 22 (2): ) M.A Leehey, R.P Munnhoz, A.E. Lang, J.A. Brunberg, J. Grigsby, C. Greco, S. Jacquemont, F. Tassone, A.M Lozano, P. Hagerman, RJ Hagerman. The Fragile X Premutation Presenting as Essential Tremor. Arch Neurol Vol 60, Jan 2003: )J. S. Adams, P. E. Adams, D. Nguyen, J. A. Brunberg, F. Tassone, W. Zhang, K. Koldewyn, S. M. Rivera, J. Grigsby, L. Zhang, C. DeCarli, P. J. Hagerman and R. J. Hagerman Volumetric brain changes in females with fragile X-associated tremor/ataxia syndrome (FXTAS) Neurology 2007;69;

PIC, IFAE, UAB Genetics: M Mila L Rodriguez A Sanchez Neurology: J Pagonabarraga J Kulissevsky E Muñoz E Tolosa Neuroradiology: B Gómez J Ruscalleda M De Juan F Núñez Collaborators: O Lopez G Llebaria G Monté G Sanchez M Delfino Y Vives Patients and Controls Hospital Clinic/IDIBAPS H Santa Creu i Sant Pau MR technical staff Acknowledgements FIS 07/770